[Drugs]
1. GLP-1 weight-loss drug is sold worldwide, and the battle for the new force starts again.
The annual sales of GLP-1 drugs will account for 9% of the overall global prescription drug market, indicating that diabetes and weight management as the core of the treatment of the drug, the market position is greatly enhanced, and gradually rewrite the map of chronic disease treatment, the reason for this is that the clinical efficacy of the new GLP-1 weight loss drugs is remarkable, the average weight loss of nearly 20%, the effect is similar to gastric reduction surgery; GLP-1 drugs share the The proportion of prescription signatures for global diabetes is rapidly climbing, and will increase from 8% in 2023 to 12% in 2026. With the convenience of injecting only B times per week, which is significantly better than the cumbersome administration of insulin 3 times per day, GLP-1 drugs are accelerating to replace insulin as the mainstay of type 2 diabetes treatment, as well as the continuous expansion of the therapeutic indications of GLP-1 drugs. The adoption of medical insurance subsidy policies and the rapid growth of commercial insurance coverage will lead to the continuous expansion of the patient population.